Fibromyalgia is a clinical syndrome wherein the patient experiences generalized pain and fatigue that cannot be explained by the presence of any other disorder.
It is often considered to be psychosomatic or psychogenic in nature.
It is found in approximately 2% of the population and the prevalence increases with age, most common in women 20-55 year of age
Use of active transcutaneous electrical nerve stimulation (TENS) in fibromyalgia (FM) patients receiving treatment results in a favourable reduction in movement-evoked pain, according to the results of a trial.
Fibromyalgia patients with comorbid insomnia more often receive prescription medications for fibromyalgia and use ambulatory care services relative to their counterparts without the sleep disorder, according to a study, suggesting that comorbidity with insomnia substantially increases its burden.
An assessment system consisting of a wearable device and a smartphone app promises reliable recording of pain in individuals with chronic pain, including fibromyalgia. The resulting data accurately reflect pain status and help alleviate pain, according to the results of a pilot study.
Tobacco use in patients with fibromyalgia leads to cognitive dysfunction, in addition to worsening of fibromyalgia symptoms and quality of life and aggravation of sleep problems and anxiety, a study has found.
The question of whether to exercise or not typically emerges in the setting of chronic pain, as patients fear that moving may contribute to exacerbate their condition. Yet, exercise does exert hypoalgesic effects on chronic pain conditions however variable these effects are, according to a senior physiotherapist who spoke at the Singapore Health & Biomedical Congress 2018.
Fibromyalgia occurs commonly in patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis, with disease activity seemingly greater in the presence of fibromyalgia, a study reports.
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.